2022
Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for Patients With Neovascular Age-Related Macular Degeneration
Sood S, Mandell J, Watane A, Friedman S, Parikh R. Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for Patients With Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology 2022, 140: 716-723. PMID: 35708679, PMCID: PMC9204613, DOI: 10.1001/jamaophthalmol.2022.1819.Peer-Reviewed Original ResearchConceptsRanibizumab port delivery systemPort Delivery SystemBevacizumab injectionIntravitreal ranibizumabNeovascular AMDBimonthly injectionsIntravitreal anti-vascular endothelial growth factor injectionsAnti-vascular endothelial growth factor injectionsIntravitreal anti-VEGF injectionsEndothelial growth factor injectionsTotal direct medical costsAnti-VEGF injectionsIntravitreal bevacizumab injectionGrowth factor injectionsDirect medical costsAge-related macularMedicare reimbursement ratesAflibercept injectionsNeovascular AgeFactor injectionsIntravitreal injectionMacular degenerationMAIN OUTCOMERanibizumabMedical costs
2021
Fecal Microbial Transplant in Individuals With Immune-Mediated Dry Eye
Watane A, Cavuoto K, Rojas M, Dermer H, Day J, Banerjee S, Galor A. Fecal Microbial Transplant in Individuals With Immune-Mediated Dry Eye. American Journal Of Ophthalmology 2021, 233: 90-100. PMID: 34214453, PMCID: PMC8678170, DOI: 10.1016/j.ajo.2021.06.022.Peer-Reviewed Original ResearchMeSH KeywordsDry Eye SyndromesFecal Microbiota TransplantationFecesGastrointestinal MicrobiomeHumansMaleMicrobiotaMiddle AgedTreatment OutcomeConceptsGut microbiome profilesT cell profileFecal microbial transplantDry eyeMicrobiome profilesMicrobial transplantDE symptomsRegulatory T-cell profilesDE symptom severityNonrandomized clinical trialPrimary outcome measureDonor microbiomeSingle healthy donorAdverse eventsMean ageClinical trialsHealthy donorsOutcome measuresStudy populationSymptom severityAdministration methodsBaseline profileGenus FaecalibacteriumTime pointsMonths